SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kohli Prashant – ‘3’ for 9/9/22 re: Acasti Pharma Inc.

On:  Friday, 9/16/22, at 4:18pm ET   ·   For:  9/9/22   ·   As:  Officer   ·   Accession #:  1171843-22-6118   ·   File #:  1-35776

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/16/22  Kohli Prashant                    3          Officer     2:23K  Acasti Pharma Inc.                Globenewswire Inc./FA

Initial Statement of Beneficial Ownership of Securities by an Insider   —   Form 3   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 3           Initial Statement of Beneficial Ownership of        HTML      7K 
                Securities by an Insider -- ownership.xml/2.6                    
 2: EX-24.1     Power of Attorney                                   HTML     10K 


‘3’   —   Initial Statement of Beneficial Ownership of Securities by an Insider — ownership.xml/2.6




        

This ‘3’ Document is an XML Data File that may be rendered in various formats:

  Form 3    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Initial Statement of Beneficial Ownership of Securities by an Insider
 
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Kohli Prashant

(Last)(First)(Middle)
C/O ACASTI PHARMA INC.
3009 BOUL. DE LA CONCORDE, SUITE 102

(Street)
LAVALA6H7T 0A3

(City)(State)(Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
9/9/22
3. Issuer Name and Ticker or Trading Symbol
Acasti Pharma Inc. [ ACST ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
XOfficer (give title below) Other (specify below)
CCO
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Shares128,138D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy) (1) 6/22/32Class A Common Shares75,0000.89 (2)D
Share Option (Right to Buy) (3) 11/12/31Class A Common Shares124,1001.63 (4)D
Explanation of Responses:
(1)  Represents 75,000 Class A common shares underlying 75,000 share options granted on 6/22/22. These share options vest on an even and quarterly basis over 36 months.
(2)  Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant.
(3)  Represents 124,100 Class A common shares underlying 124,100 share options granted on 11/12/21. These share options vest on an even and quarterly basis over 36 months.
(4)  Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant.
Remarks:
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Jason Comerford, Attorney-in-Fact 9/16/22
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Top
Filing Submission 0001171843-22-006118   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Apr. 25, 10:56:11.1am ET